Consensus Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
41.31 ^USD	-1.64%		-1.62%	-30.99%

May. 14	Transcript : Apellis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
May. 14	Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street	MT

Evolution of the average Target Price on Apellis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

de06ce7d9bcf83495a09b86b909825d8.fy2Pn9VfzhfN1faQsKfTOq3Z-KW5ruPu3XB0pnrPVwI.SHvpq4UPiWTgt8T52cuUQ8evk-Dr5Lmms0gr-TfiY0o1Q-zGuju_f7jnzg~0b9da5942584d4c316fabc0c724044b3

Analyst Recommendations on Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing	May. 09	MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating	May. 08	MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating	May. 08	MT
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating	Apr. 29	MT
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	Apr. 17	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	Apr. 09	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	Mar. 21	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	Mar. 20	MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating	Mar. 06	MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating	Mar. 04	MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre	Feb. 28	MT
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating	Feb. 13	MT
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68	Feb. 05	MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating	Jan. 30	MT
Needham Adjusts Price Target on Apellis Pharmaceuticals to $75 From $70, Maintains Buy Rating	Jan. 24	MT
Wells Fargo Raises Apellis Pharmaceuticals' Price Target to $62 From $54, Maintains Equalweight Rating	Jan. 17	MT
Baird Adjusts Apellis Pharmaceuticals' Price Target to $81 From $71, Maintains Outperform Rating	Jan. 17	MT
Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $106 From $67, Maintains Strong Buy Rating	Jan. 11	MT
Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $90 From $65, Maintains Buy Rating	Jan. 09	MT
Citigroup Adjusts Apellis Pharmaceuticals' Price Target to $67 From $70, Maintains Buy Rating	Dec. 15	MT
Oppenheimer Cuts Apellis Pharmaceuticals Price Target to $75 From $88, Maintains Outperform Rating	Dec. 15	MT
Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $67 From $93, Keeps Strong Buy Rating	Dec. 15	MT
Needham Adjusts Apellis Pharmaceuticals' Price Target to $56 From $63, Keeps Buy Rating	Dec. 14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.31 USD

Average target price

80.06 USD

Spread / Average Target

+93.81%

High Price Target

111 USD

Spread / Highest target

+168.70%

Low Price Target

50 USD

Spread / Lowest Target

+21.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Apellis Pharmaceuticals, Inc.

UBS
Wedbush
Mizuho Securities
JPMorgan Chase
Jefferies & Co.
Oppenheimer
Needham & Co.
Wells Fargo Securities
Baird
Raymond James
Goldman Sachs
Citigroup
BofA Securities
Stifel Nicolaus
HC Wainwright
Credit Suisse
Roth Capital Partners
BMO Capital
Cowen
J.P. Morgan Chase

Ratings for Apellis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar